Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07197944) titled 'Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS' on Sept. 26.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Zealand Pharma
Condition:
Short Bowel Syndrome
Intervention:
Drug: Glepaglutide
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: October 23, 2025
Target Sample Size: 90
To know more, visit https://clinicaltrials.gov/study/NCT07197944
Published by HT Digital Content S...